Report Detail

Other Global Bladder Cancer Therapeutics and Diagnostics Market Size, Status and Forecast 2019-2025

  • RnM3412671
  • |
  • 12 July, 2019
  • |
  • Global
  • |
  • 97 pages
  • |
  • QYResearch
  • |
  • Other

Global Bladder Cancer Therapeutics and Diagnostics Market Size, Status and Forecast 2019-2025

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Bladder Cancer Therapeutics and Diagnostics Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Chemotherapy
      • 1.4.3 Immunotherapy
      • 1.4.4 Radiation Therapy
      • 1.4.5 Others
    • 1.5 Market by Application
      • 1.5.1 Global Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Oncology Treatment Centers
      • 1.5.4 Ambulatory Surgery Centers
      • 1.5.5 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Bladder Cancer Therapeutics and Diagnostics Market Size
    • 2.2 Bladder Cancer Therapeutics and Diagnostics Growth Trends by Regions
      • 2.2.1 Bladder Cancer Therapeutics and Diagnostics Market Size by Regions (2014-2025)
      • 2.2.2 Bladder Cancer Therapeutics and Diagnostics Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Bladder Cancer Therapeutics and Diagnostics Market Size by Manufacturers
      • 3.1.1 Global Bladder Cancer Therapeutics and Diagnostics Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Bladder Cancer Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Bladder Cancer Therapeutics and Diagnostics Key Players Head office and Area Served
    • 3.3 Key Players Bladder Cancer Therapeutics and Diagnostics Product/Solution/Service
    • 3.4 Date of Enter into Bladder Cancer Therapeutics and Diagnostics Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2014-2019)
    • 4.2 Global Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Bladder Cancer Therapeutics and Diagnostics Market Size (2014-2019)
    • 5.2 Bladder Cancer Therapeutics and Diagnostics Key Players in United States
    • 5.3 United States Bladder Cancer Therapeutics and Diagnostics Market Size by Type
    • 5.4 United States Bladder Cancer Therapeutics and Diagnostics Market Size by Application

    6 Europe

    • 6.1 Europe Bladder Cancer Therapeutics and Diagnostics Market Size (2014-2019)
    • 6.2 Bladder Cancer Therapeutics and Diagnostics Key Players in Europe
    • 6.3 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Type
    • 6.4 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Application

    7 China

    • 7.1 China Bladder Cancer Therapeutics and Diagnostics Market Size (2014-2019)
    • 7.2 Bladder Cancer Therapeutics and Diagnostics Key Players in China
    • 7.3 China Bladder Cancer Therapeutics and Diagnostics Market Size by Type
    • 7.4 China Bladder Cancer Therapeutics and Diagnostics Market Size by Application

    8 Japan

    • 8.1 Japan Bladder Cancer Therapeutics and Diagnostics Market Size (2014-2019)
    • 8.2 Bladder Cancer Therapeutics and Diagnostics Key Players in Japan
    • 8.3 Japan Bladder Cancer Therapeutics and Diagnostics Market Size by Type
    • 8.4 Japan Bladder Cancer Therapeutics and Diagnostics Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Size (2014-2019)
    • 9.2 Bladder Cancer Therapeutics and Diagnostics Key Players in Southeast Asia
    • 9.3 Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Size by Type
    • 9.4 Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Size by Application

    10 India

    • 10.1 India Bladder Cancer Therapeutics and Diagnostics Market Size (2014-2019)
    • 10.2 Bladder Cancer Therapeutics and Diagnostics Key Players in India
    • 10.3 India Bladder Cancer Therapeutics and Diagnostics Market Size by Type
    • 10.4 India Bladder Cancer Therapeutics and Diagnostics Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Bladder Cancer Therapeutics and Diagnostics Market Size (2014-2019)
    • 11.2 Bladder Cancer Therapeutics and Diagnostics Key Players in Central & South America
    • 11.3 Central & South America Bladder Cancer Therapeutics and Diagnostics Market Size by Type
    • 11.4 Central & South America Bladder Cancer Therapeutics and Diagnostics Market Size by Application

    12 International Players Profiles

    • 12.1 Pfizer
      • 12.1.1 Pfizer Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Bladder Cancer Therapeutics and Diagnostics Introduction
      • 12.1.4 Pfizer Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2014-2019)
      • 12.1.5 Pfizer Recent Development
    • 12.2 GlaxoSmithKline
      • 12.2.1 GlaxoSmithKline Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Bladder Cancer Therapeutics and Diagnostics Introduction
      • 12.2.4 GlaxoSmithKline Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2014-2019)
      • 12.2.5 GlaxoSmithKline Recent Development
    • 12.3 Merck
      • 12.3.1 Merck Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Bladder Cancer Therapeutics and Diagnostics Introduction
      • 12.3.4 Merck Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2014-2019)
      • 12.3.5 Merck Recent Development
    • 12.4 Novartis
      • 12.4.1 Novartis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Bladder Cancer Therapeutics and Diagnostics Introduction
      • 12.4.4 Novartis Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2014-2019)
      • 12.4.5 Novartis Recent Development
    • 12.5 Bristol-Myers Squibb
      • 12.5.1 Bristol-Myers Squibb Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Bladder Cancer Therapeutics and Diagnostics Introduction
      • 12.5.4 Bristol-Myers Squibb Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2014-2019)
      • 12.5.5 Bristol-Myers Squibb Recent Development
    • 12.6 Eli Lilly
      • 12.6.1 Eli Lilly Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Bladder Cancer Therapeutics and Diagnostics Introduction
      • 12.6.4 Eli Lilly Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2014-2019)
      • 12.6.5 Eli Lilly Recent Development
    • 12.7 Roche
      • 12.7.1 Roche Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Bladder Cancer Therapeutics and Diagnostics Introduction
      • 12.7.4 Roche Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2014-2019)
      • 12.7.5 Roche Recent Development
    • 12.8 Sanofi
      • 12.8.1 Sanofi Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Bladder Cancer Therapeutics and Diagnostics Introduction
      • 12.8.4 Sanofi Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2014-2019)
      • 12.8.5 Sanofi Recent Development
    • 12.9 AstraZeneca
      • 12.9.1 AstraZeneca Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Bladder Cancer Therapeutics and Diagnostics Introduction
      • 12.9.4 AstraZeneca Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2014-2019)
      • 12.9.5 AstraZeneca Recent Development
    • 12.10 Celgene Corporation
      • 12.10.1 Celgene Corporation Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Bladder Cancer Therapeutics and Diagnostics Introduction
      • 12.10.4 Celgene Corporation Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2014-2019)
      • 12.10.5 Celgene Corporation Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.
      Based on the data from International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. Historically, bladder cancer has been associated with low patient awareness. Smoking has a high correlation with bladder cancer and this association is mostly unknown to the general public. But, in recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developed nations.
      The ecosystem for research and development for drugs for cancer is well established in North America, particularly in US. Additionally the presence of a large number of biologics companies and biopharmaceutical companies is contributing to the large size and excellent growth of bladder cancer therapeutics and diagnostics market. North America also has best adoption rates of new diagnostic modalities that are introduced in commercial space. This trend is in contrast with other regions of the world where the most widely adopted technologies for cancer diagnostics are at least a decade old. Consequently, North America is leader in terms of market size in the global bladder therapeutics and diagnostics market.
      In 2018, the global Bladder Cancer Therapeutics and Diagnostics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Bladder Cancer Therapeutics and Diagnostics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Bladder Cancer Therapeutics and Diagnostics development in United States, Europe and China.

      The key players covered in this study
      Pfizer
      GlaxoSmithKline
      Merck
      Novartis
      Bristol-Myers Squibb
      Eli Lilly
      Roche
      Sanofi
      AstraZeneca
      Celgene Corporation

      Market segment by Type, the product can be split into
      Chemotherapy
      Immunotherapy
      Radiation Therapy
      Others

      Market segment by Application, split into
      Hospitals
      Oncology Treatment Centers
      Ambulatory Surgery Centers
      Others

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Bladder Cancer Therapeutics and Diagnostics status, future forecast, growth opportunity, key market and key players.
      To present the Bladder Cancer Therapeutics and Diagnostics development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Bladder Cancer Therapeutics and Diagnostics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Bladder Cancer Therapeutics and Diagnostics. Industry analysis & Market Report on Bladder Cancer Therapeutics and Diagnostics is a syndicated market report, published as Global Bladder Cancer Therapeutics and Diagnostics Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Bladder Cancer Therapeutics and Diagnostics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,121.22
      4,681.83
      6,242.43
      3,534.87
      5,302.31
      7,069.74
      420,864.60
      631,296.90
      841,729.20
      277,226.82
      415,840.23
      554,453.64
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report